Waldencast PLC

Waldencast PLC(WALD)股票分析

$0.879

-0.041 (-4.69%)收盤時

Loading chart…
最高
0.990
開盤
0.930
成交量加權均價
0.91
成交量
277.02K
市值
478.98M
最低
0.861
成交金額
252.12K
企業價值/稅息折舊攤銷前利潤(TTM)
-0.59

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.

AI 分析 of Waldencast PLC (WALD)

賣出

Waldencast PLC is not a good buy right now due to significant financial losses and declining stock performance. The current price is $0.88, which is down 48.57% year-to-date. The RSI is at 26.413, indicating that the stock is oversold, but the forward P/E ratio is extremely high at 45.045, suggesting that the stock may be overvalued relative to its earnings potential. The main risk is the net margin, which was -140.03% in Q2 2025, indicating severe profitability issues.

估值指標

Waldencast PLC(WALD)目前預期本益比為 45.05,5 年平均預期本益比為 20.89。

預期本益比

合理
5 年均值 P/E
20.89
目前P/E
45.05
高估
140.86
低估
-99.09

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
13.82
目前EV/EBITDA
-0.59
高估
20.28
低估
7.36

預期股價營收比

低估
5 年均值 P/S
1.79
目前P/S
0.35
高估
2.88
低估
0.69

Alphio AI 對 WALD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%WALD

$3.01

情境價格

基

基準

基準 · 50%WALD

$2.59

情境價格

悲

悲觀

悲觀 · 25%WALD

$2.24

情境價格

事件時間軸

2026-10-15 (ET)

17:00:00

Waldencast Files Form 15 to Terminate Registration

2026-09-24 (ET)

17:00:00

Waldencast Files Form 25 with SEC to Deregister Shares

2026-09-14 (ET)

07:00:00

Waldencast Announces Voluntary Delisting from Nasdaq

2026-09-01 (ET)

19:00:00

Middle East Violence Escalation Weighs on Markets, Tech Stocks Under Pressure

2026-06-15 (ET)

09:30:00

Waldencast Receives FDA Approval for Obagi saypha ChIQ Injectable Hyaluronic Acid Gel

資訊

WALD 常見問題 —— 由 Alphio AI 解答

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States. It operates in the Consumer Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Waldencast PLC is not a good buy right now due to significant financial losses and declining stock performance. The current price is $0.88, which is down 48.57% year-to-date. The RSI is at 26.413, indicating that the stock is oversold, but the forward P/E ratio is extremely high at 45.045, suggesting that the stock may be overvalued relative to its earnings potential. The main risk is the net margin, which was -140.03% in Q2 2025, indicating severe profitability issues.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易